Compare SAH & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAH | SUPN |
|---|---|---|
| Founded | 1997 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 1997 | 2010 |
| Metric | SAH | SUPN |
|---|---|---|
| Price | $61.54 | $40.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $88.91 | $60.50 |
| AVG Volume (30 Days) | 271.3K | ★ 737.9K |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.58 | N/A |
| Revenue | ★ $9,951,630,000.00 | $392,755,000.00 |
| Revenue This Year | $3.60 | $22.95 |
| Revenue Next Year | $4.33 | $54.39 |
| P/E Ratio | $17.67 | ★ N/A |
| Revenue Growth | ★ 0.86 | N/A |
| 52 Week Low | $54.11 | $37.54 |
| 52 Week High | $113.67 | $59.68 |
| Indicator | SAH | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 44.54 |
| Support Level | $59.30 | $40.51 |
| Resistance Level | $65.77 | $52.30 |
| Average True Range (ATR) | 2.56 | 1.82 |
| MACD | 0.71 | 0.04 |
| Stochastic Oscillator | 30.07 | 54.13 |
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 107 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores in 10 states, 16 collision centers, and 20 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 56% of new-vehicle revenue. BMW is the largest brand at about 23%. 2025 revenue was $15.2 billion, with Texas and California constituting 51% of the total. EchoPark's portion was $2.1 billion.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.